证券代码：603883 证券简称：老百姓 公告编号：2025-039 老百姓大药房连锁股份有限公司 第五届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、监事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日 发出召开第五届监事会第七次会议的通知，会议于 2025 年 8 月 25 日以现场表 决的方式召开。会议应参与表决的监事 3 名，实际参与表决的监事 3 名。本次 会议经过了适当的通知程序，会议程序符合《公司法》等有关法律法规及《公 司章程》的规定，会议及通过的决议合法有效。 二、监事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 监事会认为： （1）公司2025年半年度报告编制和审议符合法律、法规、《公司章程》和 公司内部管理制度的规定。 （2）半年度报告的内容和格式符合中国证监会和上海证券交易所的有关规 定和要求，所包含的半年度报告能全面、真实地反映公司2025年半年度经营和 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-038 老百姓大药房连锁股份有限公司 第五届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担法律责任。 一、董事会会议召开情况 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日 发出召开第五届董事会第十次会议的通知，会议于 2025 年 8 月 25 日在公司会 议室以现场加通讯表决的方式召开，本次董事会应参加表决的董事 9 名，实际 参加表决的董事 9 名，会议由董事长谢子龙先生主持。董事会秘书等相关人员 列席会议。本次会议经过了适当的通知程序，会议程序符合有关法律法规及 《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 根据《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规及 《公司章程》等规章制度，按照中国证券监督委员会发布的公开发行证券公司 信息披露内容与格式准则要求，公司编制了《2 ...

智通财经APP讯，老百姓(603883.SH)披露2025年半年度报告，报告期公司实现营收107.74亿元，同比下 降1.51%;归母净利润3.98亿元，同比下降20.86%;扣非净利润3.81亿元，同比下降20.89%;基本每股收益 0.52元。 ...

老百姓大药房连锁股份有限公司2025 年半年度报告 公司代码：603883 公司简称：老百姓 老百姓大药房连锁股份有限公司 2025 年半年度报告 1 / 205 老百姓大药房连锁股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人谢子龙、主管会计工作负责人陈立山及会计机构负责人（会计主管人员）石磊 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬 请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 报告期内，不 ...

格隆汇8月25日丨老百姓(603883.SH)公布半年度报告，报告期公司实现营业收入107.74亿元，同比下降 1.51%；实现归属于上市公司股东的净利润3.98亿元，同比下降20.86%；毛利率33.08%，同比下降1.24 个百分点。 ...

Core Viewpoint - The article discusses the phenomenon of "small essays" in the stock market, highlighting their role in manipulating stock prices and the challenges in regulating such activities [4][35][37]. Group 1: Characteristics of "Small Essays" - "Small essays" are essentially rumors or unverified information that can significantly impact stock prices, often exploiting the curiosity and speculative nature of retail investors [6][12]. - They can be categorized into five types: policy rumors, company operations, fund movements, market sentiment/conspiracy theories, and over-interpretation of public information [9][8]. - The spread of these rumors typically begins in social media circles, where they are crafted to maximize impact and reach [11][19]. Group 2: Impact on the Market - The influence of "small essays" can lead to rapid stock price changes, sometimes within minutes, as seen in the case of companies like 淳中科技 [12][20]. - The phenomenon reflects a broader trend in the market where speculative behavior is heightened, particularly in a bull market environment [30][35]. - The presence of a large retail investor base in the Chinese stock market, which often lacks access to reliable information, creates fertile ground for the proliferation of these rumors [20][36]. Group 3: Regulatory Challenges - Despite regulatory efforts to curb the spread of "small essays," their prevalence has not diminished, indicating a gap between policy and enforcement [27][28]. - The anonymity and rapid dissemination of these rumors complicate the ability of regulatory bodies to trace and penalize offenders effectively [21][37]. - The article emphasizes the need for a multi-faceted approach involving technology and collaboration among regulatory agencies to combat the issue [38]. Group 4: Future Outlook - The article suggests that while "small essays" may continue to thrive in the short term, advancements in regulatory technology and a shift towards more rational investment practices could eventually reduce their prevalence [38]. - The ongoing evolution of the market and investor behavior will determine the future landscape of information dissemination and its impact on stock pricing [36][37].

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

Core Insights - The latest data from the People's Bank of China indicates a significant cooling in the real estate market, with the total personal housing loan balance reaching 37.74 trillion yuan, reflecting a 0.1% decrease compared to the same period last year, signaling a profound transformation in the market [1][3] Group 1: Loan Dynamics - Personal housing loan balances have experienced negative growth for the second consecutive year, with this year's decline of 0.1% being less severe than last year's 2.1%, indicating that the speed of loan repayments is outpacing new loan issuance [3][5] - In the first half of this year, new housing loans amounted to only 51 billion yuan, while early repayments reached an astonishing scale, with 24 yuan being repaid for every 1 yuan of new loans issued [3][5] Group 2: Market Conditions - The decline in housing loan balances is primarily attributed to weak housing sales, with new residential sales dropping by 5.2% year-on-year to 4.42 trillion yuan in the first half of the year, affecting the growth of loan balances as over 80% of Chinese homebuyers rely on loans [5][6] - Despite the downtrend, the average down payment ratio has fallen to a historical low of 15% for both first and second homes, yet buyers remain hesitant to take on loans due to a defensive savings mentality amid income instability [5][6] Group 3: Changing Buyer Behavior - The appeal of early repayment arbitrage is diminishing as the gap between new loan rates (3.1%) and existing loan rates has narrowed to less than 0.5%, with many families that could repay early having already done so [6][7] - The proportion of homebuyers under 25 has plummeted from 17% in 2020 to 3.8% in 2025, reflecting a shift in attitudes where younger generations prefer renting over taking on long-term debt [6][7] Group 4: Market Recovery Challenges - Although the transaction volume of second-hand homes in 30 major cities increased by 12% in the first half of the year, this growth is largely superficial, as it represents a transfer of debt rather than an increase in overall loan amounts [7] - The anticipated rise in foreclosures, with an expected 210,000 new cases in 2025, poses a significant risk to the housing loan balance, as these properties may become "bad debts" [7] - Government measures to stimulate the market, including a 60% reduction in loan rates from historical highs, have not led to sustained recovery, highlighting the fragile nature of the real estate market [7]

广东开出上万家店的连锁药业大参林，老板被刑拘了要卖股票还债，公司也被处罚，私募基金股东也偷偷减持。 更不用说，行业内7家连锁药店上市公司的财报显示，连续多年净利润增长齐刷刷在去年掉头，药店行业的数据也显示，去年合计关店3.9万家，而且四个 季度内，关店速度是递增的。 行业拐点来临，曾经狂赚钱的暴利生意，真的走到头了吗？ 以前这药店，可是一条街就能开好几家的暴利生意，但是从去年开始这所谓的暴利也不太行了。即便是上市的连锁药店，也避免不了这个结局。行业拐点 来临，曾经狂赚钱的暴利生意，真的走到头了吗？ 山东本地连锁药店龙头，被老板和高管们连续多次减持，一季度门店也关了119家。 连锁药店撑不住了？老板和高管们一通减持 连锁药店漱玉平民大药房，最近被老板和高管们一通减持： 虽然实控人李文杰是第一次减持漱玉平民的股，但在一年内，这已经是漱玉平民的第四轮股东减持潮。 2024年9月25日，漱玉平民公告称，股东阿里健康(持股比例8.47%)拟减持公司股份不超过12070642股，占公司总股本的3%，减持原因为自身资金需求。 阿里健康准备出货没两个月，漱玉平民马上又迎来第二轮减持。 2024年11月6日，漱玉平民公告，公司 ...

AI芯片板块发力，多股半年报业绩增长。 8月22日早盘，A股主要股指集体走强，沪指涨0.67%，报3796.36点；深证成指涨1.32%，重回12000点；创业板指涨2.56%。 板块上，服务器、覆铜板、芯片等科技板块走强，宠物经济、航空运输、乳业等板块回调。科创50指数大涨5.25%，创2022年4月以来新高。 AI芯片板块集体上涨 今日早盘，A股AI芯片板块集体上涨，截至收盘，概念股平均涨幅达到5.7%，科德教育、云天励飞-U"20CM"涨停；海光信息、寒武纪-U涨幅均超 过10%，其中寒武纪-U盘中最高上涨14.67%，总市值一度超过中芯国际居于科创板首位。 消息面上，DeepSeek8月21日宣布，正式发布DeepSeek-V3.1。DeepSeek表示，DeepSeek-V3.1 使用了UE8M0 FP8 Scale的参数精度，UE8M0 FP8是 针对即将发布的下一代国产芯片设计，表明未来基于DeepSeek模型的训练与推理有望更多应用国产AI芯片，助力国产算力生态加速建设。 近年来，随着大模型训练、自动驾驶及端侧AI等需求快速增长，AI芯片市场规模快速扩张。根据德勤中国日前发布的《技术趋势202 ...